Changes in plasma biomarkers differentiate clinical stages of Alzheimer's disease using immunomagnetic reduction assays
Journal of Alzheimer’s Disease · 2024
DOI: 10.3233/jad-240690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Shu-Ping Chao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dementia Center, Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, tau Proteins, Biomarkers. Die Arbeit nennt 62 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Background
Many groups have been using immunomagnetic reduction (IMR) for assaying plasma amyloid-β 1-40 (Aβ 1-40 ) peptide, Aβ 1-42 peptide and total tau protein (T-Tau) in cognitively normal controls (NC), patients with amnestic mild cognitive impairment (aMCI) and Alzheimer's disease dementia (ADD). Tremendous results have been independently reported.
Objective
We used traditional knowledge databases (e.g., PubMed, Embase), papers published at international conferences, and private communications to obtain data involving the use of IMR assay for plasma biomarkers of plasma Aβ 1-40 , Aβ 1-42 , and T-Tau in NC, aMCI, and ADD.
Methods
Results of thirty studies were analyzed, including twenty-five studies published in papers, two studies presented at conferences and three unpublished studies.
Results
Among the thirty studies, there were 1189 subjects of NC, 544 aMCI patients and 853 ADD patients. The average value of plasma Aβ 1-40 in subjects significantly decreased from NC (59.72 pg/ml) to aMCI (45.92 pg/ml, p < 0.0001), which was no significant different from ADD (48.34 pg/ml, p > 0.05). The average level of plasma Aβ 1-42 significantly increased from NC (15.72 pg/ml) to aMCI (17.66 pg/ml, p < 0.0001), which was not significantly different from ADD (19.39 pg/ml, p > 0.05). However, the average level of plasma T-Tau significantly increased from NC (17.92 pg/ml) to aMCI (28.26 pg/ml, p < 0.0001), further significantly increased to AD (35.51 pg/ml, p < 0.001).
Conclusions
Plasma Aβ 1-40 , Aβ 1-42 , and T-Tau levels are able to discriminate NC from patients with aMCI and ADD. Plasma T-Tau levels are disease-severity dependent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dementia Center, Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
- Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, New Taipei City, Taiwan.
- Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Department of Neurology, Chang Gung Memorial Hospital, Linkou Medical Center and College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- Department of General Psychiatry, Taipei City Hospital Songde Branch, Taipei, Taiwan.
ORCID-Profile: Shu-Ping Chao, Chaur-Jong Hu
Zitieren
APA
Chao, S. P., Lin, W. C., Lu, C. H., Wu, H. C., Liu, H. C., & Hu, C. J. (2024). Changes in plasma biomarkers differentiate clinical stages of Alzheimer's disease using immunomagnetic reduction assays. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-240690
Vancouver
Chao SP, Lin WC, Lu CH, Wu HC, Liu HC, Hu CJ. Changes in plasma biomarkers differentiate clinical stages of Alzheimer's disease using immunomagnetic reduction assays. Journal of Alzheimer’s Disease. 2024. doi:10.3233/jad-240690
BibTeX
@article{Chao2024,
author = {Chao, Shu-Ping and Lin, Wei-Che and Lu, Cheng-Hsien and Wu, Hsiu-Chuan and Liu, Hsing-Cheng and Hu, Chaur-Jong},
title = {Changes in plasma biomarkers differentiate clinical stages of Alzheimer's disease using immunomagnetic reduction assays},
journal = {Journal of Alzheimer’s Disease},
year = {2024},
doi = {10.3233/jad-240690}
}
EUVIMED